NEW YORK (GenomeWeb News) – Invitrogen announced today that it will work with Maryland-based biotechnology company Lentigen to develop and market products and services for gene over-expression based on Lentigen’s lentiviral gene delivery technology and Invitrogen’s human gene collections and cloning and gene synthesis technologies.
Invitrogen said that it will provide Lentigen with access to its human and mouse gene libraries, which will be used in conjunction with lentiviral gene delivery systems to create new gene expression systems for mammalian cells.
Any products or services developed within the partnership will be commercialized exclusively by Invitrogen. Further terms of the alliance were not disclosed.
“Researchers will be able to easily obtain ready-to-use lentiviral particles carrying either customer-designed genetic elements or predetermined and validated gene sets from Invitrogen’s Ultimate ORF collection,” Invitrogen Vice President of Cloning and Protein Expression Nathan Wood said in a statement.